Partial
Mostly Aligned
Patient Risk:
Low
Summary
Some drug-mechanism and indication statements are supported by the provided label sections (Description, Mechanism of Action, and Indications). However, multiple claims are not supported by the provided prescribing information, including manufacturer/supplier, generic availability/patent linkage, and all pricing/insurance-related statements.
Category Scores
Accurate Statements
Ventolin HFA contains albuterol sulfate as the active ingredient.
Supported by 11 DESCRIPTION.
Albuterol is a bronchodilator that works by relaxing the muscles in the airways, making breathing easier.
Supported by 12 CLINICAL PHARMACOLOGY (12.1 Mechanism of Action) describing relaxation of airway smooth muscle via beta2-adrenergic receptor activation and resulting bronchodilation.
Albuterol inhalers are prescribed to treat bronchospasm in people with reversible obstructive airway disease such as asthma and chronic obstructive pulmonary disease (COPD).
Partially supported: label supports treatment/prevention of bronchospasm in reversible obstructive airway disease; asthma/COPD are not explicitly confirmed in the provided excerpt of 1.1.
Albuterol inhalers are prescribed to prevent bronchospasm in people with reversible obstructive airway disease such as asthma and chronic obstructive pulmonary disease (COPD).
Partially supported: label supports treatment or prevention of bronchospasm in reversible obstructive airway disease; asthma/COPD are not explicitly confirmed in the provided excerpt of 1.1.
Albuterol inhalers are used for exercise-induced bronchospasm.
Partially supported by 1.2 Exercise-Induced Bronchospasm indication.
Unsupported Statements
Generic versions of Ventolin HFA contain albuterol sulfate as the active ingredient.
Not supported by the provided label sections; labeling excerpt provided describes Ventolin HFA but does not address generic product compositions.
Ventolin HFA is manufactured by GlaxoSmithKline (GSK).
Not supported by the provided label sections.
Generic versions are produced by various pharmaceutical companies.
Not supported by the provided label sections.
The price of a prescription for Ventolin HFA without insurance can range from approximately $30 to over $80 for a single inhaler.
Not supported by the provided label sections (label does not contain pricing information).
Generic albuterol inhalers are generally priced lower than branded Ventolin HFA.
Not supported by the provided label sections (label does not contain pricing/comparative cost information).
Generic albuterol inhalers often cost between $15 and $40 without insurance.
Not supported by the provided label sections (label does not contain pricing information).
Coverage for Ventolin HFA varies by insurance provider and plan.
Not supported by the provided label sections (label does not contain insurance coverage statements).
Many insurance plans cover albuterol inhalers.
Not supported by the provided label sections (label does not contain insurance coverage statements).
The co-payment amount for Ventolin HFA depends on the specific formulary.
Not supported by the provided label sections (label does not contain copayment/formulary details).
Availability of generic versions of Ventolin HFA is tied to patent expirations.
Not supported by the provided label sections.
Generic versions of albuterol sulfate inhalation aerosol are currently available.
Not supported by the provided label sections.
Contradictions
Important Omissions
No dosage/administration, contraindications, boxed warnings, warnings/precautions, drug interactions, monitoring, or storage/handling information was provided in the AI claims dataset; however, these are material label components not addressed at all.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Unsupported claims are primarily about manufacturer identity, generic availability, and pricing/insurance. The supported clinical content concerns mechanism and indications, with no dose/safety/contraindication assertions included in the evaluated claims.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Multiple claims are not supported by the provided prescribing information, especially manufacturer/generic/availability and all pricing/insurance-related statements.
Suggested Improvement
Limit statements to label-supported content from the provided sections (e.g., active ingredient, indications for bronchospasm and exercise-induced bronchospasm, and the described mechanism of action). Remove or qualify unsupported statements about pricing, insurance, manufacturer, and generic/patent availability unless supported by label text in the supplied excerpts.